CurrentRheuma — Systemic sclerosis & Raynaud's

Endothelial IFI16 drives vasculopathy and profibrotic remodeling in systemic sclerosis by activating JAK/STAT signaling

2026-11-12T11:15:54.044Z

Research article · Rheumatology (Oxford), 2026.

Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.

2026-11-12T11:15:54.044Z

Cohort study · Arthritis Care Res (Hoboken), 2026.

Nailfold capillaroscopy by dermatoscope in systemic sclerosis: a systematic review and meta-analysis

2026-11-09T17:15:24.911Z

Meta-analysis · Clin Exp Rheumatol, 2026.

Prevalence and clinical associations of age-related clonal hematopoiesis in systemic sclerosis

2026-11-08T16:16:11.186Z

Case-control study · Rheumatology (Oxford), 2026.

Interleukin 4-receptor-α blockade in localised scleroderma: a phase 2 proof-of-concept study

2026-11-05T13:24:18.717Z

Randomized controlled trial · Ann Rheum Dis, 2026.

Kidney spatial multiomics mapping decodes scleroderma renal crisis

2026-11-05T13:24:18.717Z

Cohort study · Ann Rheum Dis, 2026.

Long-term evaluation of the effectiveness and safety of autologous haematopoietic stem-cell transplantation for systemic sclerosis (NISSC1-LTE): a cohort study

2026-11-05T13:24:18.717Z

Cohort study · Lancet Rheumatol, 2026.

Longitudinal ultrasound assesment of skeletal muscle ın systemic sclerosis: association with disease activity and severity

2026-11-05T13:24:18.717Z

Cohort study · Rheumatology (Oxford), 2026.

Sleep Disorders in Patients with Systemic Sclerosis: A Systematic Review and Meta-Analysis

2026-11-05T13:24:18.717Z

Meta-analysis · Joint Bone Spine, 2026.

Treatment patterns and outcomes of scleroderma renal crisis in the international scleroderma renal crisis survey II – An inception cohort study

2026-11-05T13:24:18.717Z

Cohort study · Semin Arthritis Rheum, 2026.

Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment

2026-11-05T13:10:58.883Z

Research article · Ann Rheum Dis, 2026.

Nicotinamide N-methyltransferase drives fibroblast activation and skin fibrosis in systemic sclerosis

2026-11-05T13:10:58.883Z

Research article · Ann Rheum Dis, 2026.

Obinutuzumab in systemic sclerosis: a multicentre retrospective case series

2026-11-05T13:10:58.883Z

Cohort study · Rheumatology (Oxford), 2026.

Outcomes of systemic sclerosis with overlapping myositis: a propensity score-matched cohort study

2026-11-05T13:10:58.883Z

Cohort study · Rheumatology (Oxford), 2026.

Survival and immunomodulatory therapy in autoimmune disease-associated progressive pulmonary fibrosis: a multicenter registry (NEREA)

2026-11-05T13:10:58.883Z

Cohort study · Rheumatology (Oxford), 2026.

Clinical and immunological features of patients with cancer-associated systemic sclerosis: An observational study

2026-11-04T23:42:37.367Z

Cohort study · Joint Bone Spine, 2023. Independent risk factors of overall cancer (multivariate analysis) — Anti-RNA Pol 3 antibodies: OR 4.12 (95% CI 1.6-10.7); P<0.01

The validity of systemic sclerosis diagnoses in two university hospitals in Finland

2026-11-04T23:40:51.898Z

Diagnostic or prognostic study · Scand J Rheumatol, 2022. PPV of a registered SSc diagnosis: PPV, 2013 ACR/EULAR classification criteria required 0.66

A Phenome-Wide Association Study of Drugs and Comorbidities Associated With Gastrointestinal Dysfunction in Systemic Sclerosis

2026-11-04T23:37:51.551Z

Research article · J Rheumatol, 2023. Associations with SSc-GI outcomes: Distinct diagnoses identified 673

Epidemiology and Survival of Systemic Sclerosis–Sarcoidosis Overlap Syndrome

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2023. Median survival: SSc-sarcoidosis median 23.4 years · SSc median 18.6 years

Evaluation of Nailfold Capillaroscopy Online Training Using the Fast Track Algorithm

2026-11-04T23:37:51.551Z

Research article · J Rheumatol, 2022. Scleroderma vs nonscleroderma pattern, mean κ (95% CI): Interrater κ, mean 0.86 (0.83-0.88) (95% CI)

Osteolysis in Systemic Sclerosis: A Scoping Review

2026-11-04T23:37:51.551Z

Research article · J Rheumatol, 2023. Included publications heterogeneous in population and inclusion criteria; no standardised method of osteolysis detection

Assessment of muscle mass using chest computed tomography-based quantitative and qualitative measurements in patients with systemic sclerosis: A retrospective study with cross-sectional and longitudinal analyses

2026-11-04T23:02:07.938Z

Cross-sectional study · Semin Arthritis Rheum, 2023. Prevalence of myopenia and/or myosteatosis: SMA 25.2% · SMI 12.1% · SMRA 69.2%

Disease specific determinants of cardiopulmonary fitness in systemic sclerosis

2026-11-04T23:02:07.938Z

Cross-sectional study · Semin Arthritis Rheum, 2022. Percent predicted peak VO2: SSc 70% · Controls 98%

Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome

2026-11-04T23:02:07.938Z

Cross-sectional study · Semin Arthritis Rheum, 2023. GI microbial composition vs GI symptom severity (total GIT 2.0 score): Increased GI symptom severity associated with decreased species diversity and differences in GI microbial composition

Juvenile and adult-onset scleroderma: Different clinical phenotypes

2026-11-04T23:02:07.938Z

Cohort study · Semin Arthritis Rheum, 2023. Clinical features and survival: Cutaneous subset: aSSc mostly limited cutaneous (74.1%), jSSc mostly diffuse cutaneous (76.7%), p<0.001

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

2026-11-04T22:58:59.711Z

Secondary analysis · RMD Open, 2023. Rate of FVC decline, placebo, by risk-factor subgroup, 52 weeks: Placebo, <18 months since first non-Raynaud symptom -167.8 mL/year

Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies

2026-11-04T22:58:59.711Z

Cohort study · RMD Open, 2023. Progression from suspected very early SSc to definite SSc (literature review), 1-15 years of follow-up: Proportion of patients with suspected very early SSc progressing to definite SSc 52%

Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study

2026-11-04T22:58:59.711Z

Cohort study · RMD Open, 2023. Patients with significant lung progression (%pFVC decline), 12 months after NTD vs the 12 months prior to NTD: Significant lung progression significantly lower at 12 months after NTD than in the previous 12 months (60% vs 17.5%, p=0.007)

Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry ‘SPRING’ of the Italian Society for Rheumatology

2026-11-04T22:58:59.711Z

Cross-sectional study · RMD Open, 2023. Prevalence of ssSSc among SSc patients: ssSSc 61 (3.4%); F/M 19/1

Ultrasound quantitative assessment of ventral finger microvasculopathy in systemic sclerosis with Raynaud’s phenomena: a comparative study

2026-11-04T22:58:59.711Z

Diagnostic or prognostic study · RMD Open, 2023. Percent vascular area and mean vascular intensity, dorsal and ventral sides — RP-SSc vs Controls; p<0.01; significantly lower in RP-SSc for both dorsal and ventral sides

Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon

2026-11-04T22:57:04.788Z

Cross-sectional study · Arthritis Res Ther, 2023. hyperspectral imaging (HSI) oxygenation parameters: Baseline deoxyHb higher and O2 sat lower in systemic sclerosis (SSc) patients vs HC p < 0.05

Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension

2026-11-04T22:57:04.788Z

Cohort study · Arthritis Res Ther, 2023. Survival, follow-up 2.4 ± 1.8 (median 2.4) years: HRC > 2% at baseline significantly associated with worse survival, univariable p = 0.018

Proteomic aptamer analysis reveals serum markers that characterize preclinical systemic sclerosis (SSc) patients at risk for progression toward definite SSc

2026-11-04T22:57:04.788Z

Cohort study · Arthritis Res Ther, 2023. Association of baseline serum proteins with progression to definite SSc (validation cohort): Endostatin, HR (CI95 2.2-47.59), p=0.003 10.23

A Multimodal Prediction Model for Diagnosing Pulmonary Hypertension in Systemic Sclerosis

2026-11-04T22:50:06.138Z

Diagnostic or prognostic study · Arthritis Care Res (Hoboken), 2023. Diagnostic performance for PH (best model): Random forest: AUC 0.92 (95% CI 0.83-1.00); sensitivity 0.95 (95% CI 0.75-1.00); specificity 0.80 (95% CI 0.56-0.94)

Assessment of the Systemic Sclerosis–Associated Raynaud's Phenomenon Questionnaire: Item Bank and Short‐Form Development

2026-11-04T22:50:06.138Z

Research article · Arthritis Care Res (Hoboken), 2023. Development of the ASRAP questionnaire: Preliminary ASRAP questionnaire items 37

Association of Symptoms of Gastroesophageal Reflux, Esophageal Dilation, and Progression of Systemic Sclerosis–Related Interstitial Lung Disease

2026-11-04T22:50:06.138Z

Secondary analysis · Arthritis Care Res (Hoboken), 2023. Association of reflux symptoms and esophageal dilation with change in QLF-LM and QILD-LM, 2 years: Baseline mean patient-reported reflux score (moderate reflux) 0.57

Association of Systemic Sclerosis With Incident Clinically Evident Heart Failure

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2023. HF hospitalization — SSc vs Non-SSc: aHR 3.26 (95% CI 2.49-4.28)

Associations Between Patterns of Esophageal Dysmotility and Extra‐Intestinal Features in Patients With Systemic Sclerosis

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2023. Clinical features associated with AC: Diffuse cutaneous disease, AC vs comparator: 38.5% vs 10.0%; P < 0.01 38.5% versus 10.0%

Blood Neutrophil Count and Neutrophil‐to‐Lymphocyte Ratio for Prediction of Disease Progression and Mortality in Two Independent Systemic Sclerosis Cohorts

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2022. Prediction of serially obtained FVC% and MRSS and of long-term mortality by baseline neutrophil count and NLR (GENISOS): Baseline neutrophil count → lower serial FVC% b = -4.74, P = 0.009

Circulating CTRP9 Is Associated With Severity of Systemic Sclerosis–Associated Interstitial Lung Disease

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2022. FVC% trajectory by CTRP9 group (mixed model), 48 months — High CTRP9 vs Low CTRP9; P = 0.23; worse lung function but not a different trajectory

Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data

2026-11-04T22:50:06.138Z

Secondary analysis · Arthritis Care Res (Hoboken), 2022. FVC longitudinal trend after accounting for participant loss: HSCT 0.77 percentage points/year · CYC -3.70 /year

Clinical Phenotypes of Patients With Systemic Sclerosis With Distinct Molecular Signatures in Skin

2026-11-04T22:50:06.138Z

Cross-sectional study · Arthritis Care Res (Hoboken), 2023. Inflammatory intrinsic subset (IS) 22.1 ± 9.9 · dcSSc 19.4 ± 9.4

Damage Trajectories in Systemic Sclerosis Using Group‐Based Trajectory Modeling

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2022. Damage trajectory group membership, first 5 annual visits: Low 54.6% · Medium 36.2% · High 10.3%

Patient and Physician Global Assessments of Disease Status in Systemic Sclerosis

2026-11-04T22:50:06.138Z

Research article · Arthritis Care Res (Hoboken), 2023. Formats, wording and clinimetric properties of PtGA and PhGA in SSc RCTs: Marked heterogeneity in the wording and measurement scales of the global assessments applied in RCTs

Perceived Cognitive Function in People With Systemic Sclerosis: Associations With Symptoms and Daily Life Functioning

2026-11-04T22:50:06.138Z

Cross-sectional study · Arthritis Care Res (Hoboken), 2023. Perceived mild-to-severe cognitive dysfunction: Patients with SSc perceiving mild-to-severe cognitive dysfunction 59 (56%)

Physical Therapy in Systemic Sclerosis: The Patient Perspective

2026-11-04T22:50:06.138Z

Cross-sectional study · Arthritis Care Res (Hoboken), 2022. Used or using PT in primary care 128 (63%)

Reporting and Representativeness of Race, Ethnicity, and Socioeconomic Status in Systemic Sclerosis Randomized Trials: An Observational Study

2026-11-04T22:50:06.138Z

Meta-analysis · Arthritis Care Res (Hoboken), 2023. Studies providing information about race/ethnicity: about one-third, with no improved reporting over time

Slow Colonic Transit in Systemic Sclerosis: An Objective Assessment of Risk Factors and Clinical Phenotype

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2022. Slow colonic transit 48 (48%)

Ultrasound Classification of Finger Pulp Blood Flow in Patients With Systemic Sclerosis: A Pilot Study

2026-11-04T22:50:06.138Z

Research article · Arthritis Care Res (Hoboken), 2022. finger pulp blood flow (FPBF) grade 0: SSc 22.1% · Controls 3.3%

A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s

2026-11-04T22:45:44.055Z

Randomized controlled trial · Rheumatology (Oxford), 2022. AUC for rewarming, all eight fingers combined, 15 min: C21 geometric mean 20 046 °C*s · Placebo geometric mean 19 558 °C*s